Monopar Therapeutics Inc. (NASDAQ:MNPR) COO Andrew Cittadine Purchases 12,000 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) COO Andrew Cittadine acquired 12,000 shares of the stock in a transaction dated Thursday, June 13th. The shares were bought at an average cost of $0.91 per share, with a total value of $10,920.00. Following the transaction, the chief operating officer now directly owns 129,624 shares of the company’s stock, valued at $117,957.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Cittadine also recently made the following trade(s):

• On Monday, June 17th, Andrew Cittadine acquired 12,000 shares of Monopar Therapeutics stock. The shares were bought at an average cost of $0.90 per share, with a total value of $10,800.00.
• On Monday, June 3rd, Andrew Cittadine bought 12,000 shares of Monopar Therapeutics stock. The shares were acquired at an average price of $0.76 per share, with a total value of $9,120.00.
• On Friday, May 31st, Andrew Cittadine purchased 12,000 shares of Monopar Therapeutics stock. The stock was purchased at an average price of $0.64 per share, with a total value of $7,680.00.
• On Wednesday, May 29th, Andrew Cittadine purchased 12,000 shares of Monopar Therapeutics stock. The stock was purchased at an average price of $0.64 per share, with a total value of $7,680.00.

Monopar Therapeutics Trading Down 7.4 %

MNPR stock traded down $0.07 during mid-day trading on Monday, hitting $0.87. The stock had a trading volume of 95,174 shares, compared to its average volume of 2,991,488. Monopar Therapeutics Inc. has a 52 week low of $0.27 and a 52 week high of $1.73. The firm has a market capitalization of $15.22 million, a P/E ratio of -1.67 and a beta of 1.15. The firm has a fifty day simple moving average of $0.70 and a 200 day simple moving average of $0.59.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. As a group, equities analysts expect that Monopar Therapeutics Inc. will post -0.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on MNPR shares. Jonestrading raised shares of Monopar Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research report on Thursday, April 11th. HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of Monopar Therapeutics in a research report on Friday, May 10th.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.